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I&tract xxR/KxRxxSxx sequences were phosphorylated with 
high efficiency by both p70 S6 kinase (~70S~~) and MAPKAP 
hinase-1. The best substrate for MAPKAP kinase-1 
(KKKNRTLSVA) was phosphorylated with a K,,, of 0.17 PM, 
and the best substrate for ~70%~ (KKRNRTLSVA) with a Km of 
1.5 PM. The requirement of both enzymes for Arg/Lys at position 
n-5 could be partially replaced by inserting basic residues at other 
positions, especially by an Arg at n - 2 or n - 4. MAPKAP 
hinase-1 (but not ~70~~~) tolerated lack of any residue at n - 5 
if Arg was present at n - 2 and n - 3. ~70~~ (but not ~90%~) 
tolerated Thr at position n and absence of any residue at n + 2. 
The peptide KKRNRTLTV, which combined these features, was 
relatively selective for p70s6K having a 50-fold higher V,,,,,/K,,, 
than MAPKAP kinase-1. Inactivation of the N-terminal kinase 
domain of MAPKAP kinase-1, which is 60% identical to p70S6K, 
abolished activity towards all peptides tested, but the enzyme 
retained 3040% of its activity if the C-terminal kinase domain 
kvas inactivated. 
,<ey words: S6 kinase; MAP kinase; Protein kinase; Ribosomal 
: brotein S6; Protein phosphorylation; Site-directed mutagenesis 
1. Introduction 
p70 ribosomal S6 kinase (~70~~~) [l] and p90 ribosomal pro- 
rein S6 kinase (~90’~~) [2] were originally identified as enzymes 
vhich phosphorylate ribosomal protein S6 in vitro. These ki- 
lases both become activated within minutes after cell stimula- 
‘ion by insulin and growth factors, but via distinct signalling 
‘Jathways. p90rSk IS activated by the p42 and p44 mitogen-acti- 
rated protein (MAP) kinases [3,4], but ~70~~~ is activated via 
t pathway that is blocked by rapamycin, a drug which does not 
nhibit the activation of MAP kinases or ~90’“~ [5,6]. Rapamy- 
:in prevents the growth factor-induced phosphorylation of S6 
n several mammalian cells [7], indicating that ~70~~~ is respon- 
,ible for S6 phosphorylation in vivo. For this reason, and to 
lvoid confusion with ~70~~~ and the nuclear form ~85~~~ which 
s produced using an alternative initiation site [8,9], we have 
uggested that ~90”” be called MAP kinase-activated protein 
MAPKAP) kinase- 1 [lo]. 
Rapamycin induces arrest of the eukaryotic cell division 
‘Corresponding author. Fax: (44) (1382) 22-3778. 
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cycle in G 1 [ 111 and prevents the interleukin-2 induced prolifer- 
ation of T-cells [ 121, suggesting that S6 may not be the only in 
vivo substrate for ~70~~~. Similarly, MAPKAP kinase- 1 phos- 
phorylates many proteins in vitro, including tyrosine hydrox- 
ylase [lo], the glycogen-binding (GJ subunit of protein phos- 
phatase-1 (PPl) in striated muscle [13] and glycogen synthase 
kinase-3 (GSK3) [14]. GSK3 may be a physiological substrate, 
because it is phosphorylated at the serine residue targetted by 
MAPKAP kinase-1 in vitro when A431 cells are stimulated by 
EGF [IS] and in NIH 3T3 cells the phosphorylation of GSK3 
is suppressed by transfection with dominant negative forms of 
MAP kinase kinase [16]. Coexpression with MAPKAP kinase-1 
also enhances the phosphorylation (inactivation) of GSK3 in 
HeLa cells stimulated with phorbol esters [17]. ~70~~~ phospho- 
rylates GSK3 at the same serine residue as MAPKAP kinase- 1 
in vitro, but rapamycin fails to prevent the inhibition of GSK3 
by EGF in A431 cells [15] or by insulin in L6 or CHO cells 
[l&19]. Thus p70 S6K is not essential for the inhibition of GSK3 
in vivo. 
Several studies originally suggested that the substrate speci- 
ficities of p70ShK and MAPKAP kinase-1 were distinct. The 
motif RxRxxS was found to be critical for the specificity of 
p70SbK [20], whereas MAPKAP kinase-1 was found to phos- 
phorylate tyrosine hydroxylase and the G, subunit of PPl at 
RRxS motifs [10,13,21]. Moreover, small peptides of the type 
RRxSxx were phosphorylated with quite low (50 PM) KM val- 
ues by MAPKAP kinase-1 [22]. In contrast, several substrates 
containing these motifs were not phosphorylated by p70S’jK [23]. 
However, despite these differences MAPKAP kinase-I and 
p70ShK both phosphorylate the same serine residue in GSK3 [ 161 
and target the same serine in S6 preferentially in vitro [20,22], 
both of which lie in RxRxxS motifs. These observations, and 
further experiments with a different panel of synthetic peptides 
[24], indicated that although an Arg located three residues N- 
terminal to the phosphorylated serine (position n - 3) is essen- 
tial for phosphorylation by MAPKAP kinase-I , an Arg at n - 2 
is not. These findings have led us to compare the specificities 
of p70= and MAPKAP kinase-1 in greater detail. We now 
show that, although phosphorylation can be enhanced if Arg 
is present at n - 2, MAPKAP kinase-1 greatly prefers Arg at 
n - 5 and the requirements of p70ShK and MAPKAP kinase-I 
for basic residues are very similar. Nevertheless. we have been 
able to exploit other differences in the specificity requirements 
of these enzymes to generate the first peptide substrate which 
shows a high degree of selectivity for p70shK over MAPKAP 
kinase-1. We also demonstrate that it is the N-terminal kinase 
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domain of MAPKAP kinase-1 which is essential for phospho- 
rylating peptides with either RxRxxS or RRxS motifs. 
2. Material and methods 
2.1. Materials 
The peptide LRRASLG (Kemptide) was purchased from Sigma 
Chemical Co. (Poole, UK), and the 19-residue peptide inhibitor of 
cyclic AMP-dependent protein kinase (termed PKI) [25] and other 
peptides synthesised at Dundee on an Applied Biosystems 431A peptide 
synthesiser. Their purity was established by high performance liquid 
chromatography and fast-atom-bombardment mass spectrometry and 
their concentrations were determined by quantitative amino acid anal- 
ysis. MAPKAP kinase-lg (~90”~~~) from rabbit skeletal muscle [4] was 
provided by Dr. C. Sutherland at Dundee. Reagents for cell culture 
were purchased from GIBCO (Paisley, UK), antibody 12CA5 from 
Boehringer (Lewes, UK), Protein G-Sepharose from Sigma (Poole, 
UK) and microcystin from Calbiochem. PD 98059 was a generous gift 
from Dr. Alan Saltiel (Parke-Davis, MI, USA). 
2.2. Partial pur@cation ofp70 S6 kinase 
Ten rats were injected with cycloheximide (5 mg/lOO g of body 
weight) to activate ~70s~~. One hour later, the rats were killed by 
cervical dislocation, the livers removed and homogenised in 2.5 ~01s. 
of 15 mM sodium pyrophosphate, 5 mM EDTA, 25 mM NaF, 1 mM 
benzamidine, 1 mM sodium orthovanadate, 0.1 mM phenylmeth- 
ylsulphonyl fluoride (PMSF) and 0.1% (by vol.) 2-mercaptoethanol, pH 
6.8, and centrifuged for 30 min at 38,000 x g. The supernatant was 
passed through a buchner funnel containing 10 g (dry weight) QAE- 
Sephadex equilibrated in 25 mM Tris-HCl, 1 mM EDTA, 25 mM NaF, 
1 mM sodium pyrophosphate, 1 mM benzamidine, 1 mM sodium 
orthovanadate, 0.1 mM PMSF and 0.1% (by vol.) 2-mercaptoethanol, 
pH 7.0 (Buffer A). After washing with Buffer A containing 0.1 M NaCl 
until the absorbance at 280 nm was CO. 1, ~70s~~ was eluted with Buffer 
A containing 0.5 M NaCl. The eluate was dialysed against 20 mM 
triethanolamine-HCI, 1 mM EDTA, 1 mM benzamidine, 5% (by vol.) 
glycerol, 0.03% (by mass) Brij-35 and 0.1% (by vol.) 2-mercaptoethanol, 
pH 7.4 (Buffer B), and chromatographed on a column of Q-Sepharose 
(10 x 1.6 cm) equilibrated in Buffer B. The column was developed with 
a 400 ml linear gradient to 0.7 M NaCl and the most active fractions, 
eluting between 300 and 350 mM NaCl, were pooled, dialysed against 
20 mM Tris-HCl, 1 mM EDTA, 0.03% (by mass) Brij-35, 5% (by vol.) 
glycerol and 0.1% (by vol.) 2-mercaptoethanol, pH 7.0 (Buffer C) and 
chromatographed on a 5 ml HiTrap column of heparin-Sepharose 
(Pharmacia) equilibrated in Buffer C. The column was developed with 
a 200 ml linear NaCl gradient to 1 M NaCl and the most active 
fractions, eluting between 300 and 360 mM NaCl were pooled, dialysed 
against Buffer C containing 50% (by vol.) glycerol and stored at - 20°C. 
The preparation was free of MAPKAP kinase-1 and other known 
kinases, because it was devoid of activity towards the peptide 
LRRASLG (Kemptide) [23], inactivated by incubation with PP2A, and 
all the activity towards the substrates (G245/G246)S6218-249 [26] and 
KRRRLASLAA [20] was immunoprecipitated by the anti-p70S6K anti- 
bodies described in [27]. 
2.3. Assay 0fp70s~~ and MAPKAP kinase-I 
p70S6K and MAPKAP kinase-1 were diluted to 2.0 U/ml in 50 mM 
MOPS, pH 7.0, 0.1 mM EGTA, 0.1% (by vol.) 2-mercaptoethanol, 
0.03% (by mass) Brii 35. The standard assays (50~1) contained 50 mM 
MOPS, pH 7.0, 0.1 mM EGTA, 0.1% (by vol.) 2-mercaptoethanol, 2.5 
uM PKI. 0.2 U/ml ~70s~~ or MAPKAP kinase-1. the Deutide (G? 
‘G2*)S62’c249 (30 PM), 10 mM MgCl, and 0.1 mM [r-i2PjATP (20& 
1000 cpm/pmol). After incubation for 10-15 min at 30°C reactions 
were terminated and analysed as in [27]. When assaying immunoprecip- 
itated MAPKAP kinase-1, the tubes were agitated continuously 
throughout the assay to keep the enzyme in suspension. One unit of 
activity was that amount which catalysed the phosphorylation of 
1 nmol of S6 peptide in 1 min. The phosphorylation of other peptides 
was carried out in an identical manner. Michaelis constants (&J and 
V,,, values were determined from double reciprocal plots of 1lVagainst 
I/S, where S was the substrate concentration. The standard errors for 
all reported kinetic constants was < f 20%, and the data reported are 
given as mean values for at least three independent determinations. 
2.4. Consmrction of site-speciJic mutant plasmids 
pBluescript phagemid containing DNA encoding a nonapeptide that 
corresponds to an epitope in the influenza haemagglutinin (HA 1) 
immediately followed by cDNA encoding the rat MAPKAP kinase-la 
(~90’“~~‘) [28] was modified by PCR mutagenesis to mutate Asp205 or 
Asp=’ to Ala. The AlaZo5 mutant was produced by digestion of 
pBluescript HA-MAPKAP kinase-lcr with BgflI and EcoNI and liga- 
tion of a mutated BgflI-EcoNI digested PCR fragment. The PCR frag- 
ment was produced using pBluescript HA- MAPKAP kinase-la as 
template and two primers, one primer that contained a unique BgfiI 
restriction site (underlined) 5’-CAA CGA CAT CTC TAT CAC ACA 
CCA CGT CAA GG-3’, and the other that contained both a unique 
EcoNI restriction site (underlined) and the mutation (bold type), 5’- 
AAT GGC CTC CTT GCT CAG CCC AAA GGC ACT GAG-3’). 
The reaction cozns and subseauent ourification of DNA were as 
described previously [29], except that oligonucleotides were annealed 
for 1 min at 65°C. The Alas5’ mutant was produced by digestion of 
pBluescript HA-MAPKAP kinase-1 with SnaI and NdeI and ligation 
of a mutated SnaI-NdeI digested PCR fragment that was created by a 
two-step PCR. In the first PCR, two overlapping fragments, termed 
here A and B, were prepared using pBluescript HA-MAPKAP kinase-1 
as template. Fragment A was amplified with an outer forward primer 
(5’-CGA CAG TAA GCA CGT ATA CCT GGT G-3’) covering a 
uniaue SnaI site and an inner reverse mimer (S-GCA AAG CCA AAG 
GCG CAT ATT CGT AGG-3’). Fragment-B was amplified with an 
inner forward primer (S-CCT ACG AAT ATG CGC CTT TGG CTT 
TGC-3’) and an outer reverse primer (5’-CCC AGG CTC CAT ATG 
TCA CAG CC-3’) that covers a uniaue NdeI site. The react- 
tions and isolation of Fragments A and B were as described above. The 
two fragments were then annealed and used as a template for second- 
round PCR amplification as described [29]. The DNA was digested with 
&a1 and Ndel, purified on a 1% agarose gel using Geneclean (Stratech 
Ltd., Luton, UK) and subcloned into the Snal-NdeI digested 
pBluescript phagemid containing wild type DNA. 
The sequences of the MAPKAP kinase-la mutants were checked 
using an Applied Biosystems automatic DNA sequencer using specific 
oligonucleotide primers. The mutant and wiId type MAPKAP kinase- 
la DNA constructs were expressed by subcloning from the pBluescript 
phagemid vector into the pMT2 vector using the unique EcoRI site. 
3. Results 
3. I. Comparison of the substrate spec@city of’ MAPKAP 
kinase-lg and plQS6k 
We have previously analysed the substrate specificity of the 
stress-activated enzyme MAPKAP kinase-2 using a set of syn- 
thetic peptides related to the N-terminal sequence of glycogen 
synthase, and compared its specificity to that of MAPKAP 
kinase-1 [24]. Like MAPKAP kinase-1, MAPKAP kinase-2 is 
activated by the p42 and p44 MAP kinases in vitro, but in vivo 
it is activated by a distinct MAP kinase homologue which 
responds to cellular stresses and the cytokine interleukin- 1 [30]. 
The minimum sequence required for phosphorylation by 
MAPKAP kinase-2 is L/FxRxxSxx [24]. The ‘parent’ peptide 
of this series, KKLNRTLSVA, was phosphorylated by 
MAPKAP kinase-2 with a V,,, of 13 pmol min-’ . mg-’ and a 
K,,, of 18 PM, but phosphorylation was abolished if the Leu at 
position n - 5 was changed to Lys or Glu. In contrast, substitu- 
tion of the Leu by Lys was not deleterious to MAPKAP kinase- 
1, and actually doubled the rate of phosphorylation at a peptide 
concentration of 30 ,uM [24]. More detailed kinetic analysis has 
now revealed that replacing the Leu at IZ - 5 with Lys, not only 
abolishes phosphorylation by MAPKAP kinase-2, but drasti- 
cally decreases the K,,, for phosphorylation by MAPKAP ki- 
nase-1 from 30,~M to < 0.2,~M (Table 1). The resulting peptide, 
KKKNRTLSVA, is therefore the best substrate for MAPKAP 
kinase-1 identified so far, with a similar I’,,,, but a six-fold 
lower K,,,, than (G245,G246)S62’8~249 (Table I), a 32 residue pep- 
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T.tble 1 
C omparison of the substrate specificities of MAPKAP kinase-1 and p70 S6 kinase 
r\ umber Peptide MAPKAP kinase-1 
VI%+. KID V,,,IK, 
p70 S6 kinase 
V oL’“,al Km Vm/Km 
@mol.min-‘.rng-‘) @M) 
min-’ 
we’) @Ml ~~ 
KKKNRTLSVA 1.55 0.17 9.3 0.89 3.3 0.27 
KKRNRTLSVA 1.80 0.71 2.5 1.52 1.5 1.01 
KKLNRRLSVA 1.17 1.5 0.78 0.21 9.7 0.02 
1 KKTiNRi?LSVA 1.73 2.8 0.62 1.29 1.6 0.80 
i KKrRR’?iSVA 1.35 2.3 0.59 0.38 2.3 0.16 - 
, AARNRTLSVA 0.88 1.9 0.46 1.01 7.3 0.14 
I KKRNKTLSVA 0.84 17 0.05 0.76 34 0.02 -- 
1 KKLNRTLSVA 0.86 30 0.03 0.27 47 0.006 
) KKFNRTLSVA 1.85 59 0.03 0.41 > 500 10.001 
I) AAiSNRRLSVA 0.29 9.2 0.03 0.12 140 < 0.001 
1 I AAKNRTLSVA 0.52 28 0.02 0.58 350 0.002 
I! KKENRTLSVA 1.08 96 0.01 0.05 130 <O.OOl 
13 KKKNKTLSVA 0.16 > 500 <O.OOl 0.03 49 <O.OOl -- 
it GRPRTSSFAEG 0.79 0.76 1.0 1.27 0.9 1.41 
Ii KRRRLASLAA 1.30 0.27 4.8 1.53 1.9 0.81 
Ii (G2JS,G24h)S6” 8~ 249 1.76 0.93 1.9 I .24 1.9 0.65 
!7 LRRASLG 1.94 23 0.09 0 0 
13 SPQPSRRGSESSEEVYV 1.07 25 0.04 0 0 
1 eptides 1-13 are variants of the peptide KKKNRTLSVA, peptide 14 corresponds to the sequence in GSK3 phosphorylated by both MAPKAP 
b inase-1 and p70 S6 kinase, while peptide 15 is related to the sequence surrounding the serine in ribosomal protein S6 phosphorylated by both enzymes. 
I eptide 16 is the standard peptide substrate which has been used to assay MAPKAP kinase-1 and p70 S6 kinase. Peptide 17 (Kemptide) is the standard 
h rbstrate for cyclic AMP-dependent protein kinase and peptide 18 corresponds the sequence surrounding the serine residue (bold type) in the 
( i-subunit of PPl which is phosphorylated by MAPKAP kinase-1 in vitro. K,,, values were determined from Lineweaver-Burke plots and If,,,,, values 
1 ere compared to that reported for peptide 16 in [23]. Further experimental details are given in section 2. 
t de related to the C-terminus of ribosomal protein S6 which 
1 as been used to assay MAPKAP kinase-1 previously [23]. The 
I&, for KKKNRTLSVA was at least two orders of magnitude 
I jwer than the synthetic peptide substrates for MAPKAP ki- 
I ase-1 studied previously which contain RRxS motifs [22]. 
The Leu-to-Lys substitution creates a KxRxxS sequence, 
similar to the RxRxxS motif which is critical for substrate 
:ecognition by ~70~~~ [20]. We therefore decided to com- 
i fare the specificities of MAPKAP kinase-1 and ~70~~~ using 
ariants of the peptide KKKNRTLSVA. These experiments 
1 Table 1) confirmed the importance of Arg at position n - 3 
( nd Arg or Lys at position n - 5 for both protein kinases, 
i leptides containing a KIRxRxxS motif being phosphorylated 
with very low K,,, values (see peptides 1, 2, 4, 6, 14 and 15). 
( Ihanging the Arg at position II - 3 to Lys increased the K,,, for 
ither kinase over 20-fold (compare peptides 2 and 7 in Table 
), while substitution of a basic residue at n - 5 by Leu, Pro or 
‘Iilu increased the K,, for peptide phosphorylation even more 
and also reduced the V,,,,,, particularly with ~70~~~ (compare 
peptides 1 and 2 with peptides 8,9 and 12). The presence of Lys 
at positions n - 6 and n - 7 also improved phosphorylation by 
both MAPKAP kinase-1 and p70S6K, especially when the resi- 
due at position n - 5 was Lys rather than Arg (compare peptide 
1 with 11, 2 with 6, and 3 with 10). Another similarity between 
the two protein kinases was that the large rise in K,,, resulting 
from lack of an Arg at IZ - 5 could be avoided by inserting Arg 
at positions n - 2 (compare peptides 2, 3 and 8) or n - 4 (com- 
pare peptides 2, 5 and 8). However, the presence of Arg at 
positions n - 2 or n - 4 could not alleviate the large decrease 
in the V,,,,, of ~70~~~ associated with lack of a basic residue at 
position n - 5. 
3.2. A peptide substrate with a high degree of selectivity for 
p70S6K over MAPKAP kinase-I 
The similar requirement of MAPKAP kinase-1 and ~70~~~ 
for basic residues suggested that it might be difficult to develop 
-able 2 
Development of a peptide substrate with a high degree of selectivity for p70 S6 kinase over MAPKAP kinase-1 
MAPKAP kinase-1 p70 S6 kinase 
Peptide V,,X K, V,,,IK, V max Km 
@mol. min-’ mg-‘) f&M) 
VmxIKm 
@mol t min-’ mg-‘) (uM) 
KKRNRTLSVA 1.80 0.73 2.5 1.52 1.5 1.0 
KKRNRTLSV 2.03 16 0.13 1.43 1.4 1.0 
‘. KKRNRTLTV 0.27 40 0.007 1.47 4.8 0.31 
_. KKRNRTLTK 0.07 180 c 0.001 1.53 31 0.05 
‘. RNRTLTV- 0.20 53 0.004 1.10 11 0.10 
). KKRNRAITV 0.27 82 0.003 I .22 38 0.03 -- 
KKRNRGLTV 0.13 96 0.001 0.75 119 0.006 -- 
:. KKRNRNLTV 0.04 100 < 0.001 0.98 62 0.02 -- 
‘. KKRNRTLSEA 0.02 > 500 < 0.001 0.10 > 500 <O.OOl 
(Changes from the parent peptide KKRNRTLSVA are underlined. K,,, values were determined from Lineweaver-Burke plots and V,,,,, values were 
letermined relative to peptide 16 in Table 1, whose V,,,,, was reported in [20]. Further experimental details are given in section 2. 
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a specific peptide substrate for p70S’jK by making amino acid 
substitutions N-terminal to the site of phosphorylation, and 
prompted a comparison of the C-terminal requirements of each 
enzyme. With the peptide series used previously, we found that 
for efficient phosphorylation by MAPKAP kinase-1, the resi- 
due at position n + 1 must not be Pro or Lys, a residue must 
be present at position n + 2, and the residue at position n must 
be Ser and not Thr [24]. The effect of making these replace- 
ments was therefore examined using KKRNRTLSVA as the 
parent peptide, since this was the best substrate for ~70~~~ 
identified in Table 1 (K,,, = 1.5 PM). Like MAPKAP kinase-1, 
~70~~~ greatly disliked Pro at position n + 1 (compare peptide 
1 with peptide 9 in Table 2). However, elimination of the Ala 
at position n + 2 had no effect on phosphorylation by p70S6K, 
whereas it increased the K,,, for MAPKAP kinase-1 over 20-fold 
(compare peptides 1 and 2 in Table 2). Moreover, substituting 
the Ser in peptide 2 by Thr decreased the V,,,,, of MAPKAP 
kinase-I by 7-g-fold, but did not affect the V,,, of ~70~~~ and 
only increased the K,,, to 4.8 ,uM (compare peptides 2 and 3 in 
Table 2). Thus two changes converted KKRNRTLSVA from 
a peptide with a 2.5-fold higher V,,,IK,,, for MAPKAP kinase- 
1, to one (KKRNRTLTV) which had a 4(1-50-fold higher V,,,l 
K,,, for ~70~~~. Changing the valine residue in KKRNRTLTV 
to Lys produced a peptide with a similar selectivity for ~70~~~ 
over MAPKAP kinase-1 in terms of V,,,,,/K,,,, but the K,,, for 
p70SbK was much higher (compare peptides 1 and 4 in Table 2). 
MAPKAP kinase-1 phosphorylated both Thr residues in the 
peptide KKRNRTLTV (data not shown), but substitution of 
the first Thr by Ala, Gly or Asn did not improve selectivity, 
because these changes were deleterious to ~70~~~ as well as to 
MAPKAP kinase-1 (peptides 668 in Table 2). Changing the 
first threonine in KKRNRTLTV to Arg or Lys made this 
peptide a slightly worse substrate for ~70~~~ and a better sub- 
strate for MAPKAP kinase-1 and therefore decreased selectiv- 
ity for ~70~~~. Removing both Lys residues at the N-terminus 
of KKRNRTLTV also failed to improve selectivity for ~70~~~ 
(peptide 5 in Table 2). 
3.3. The N-terminal kinase domain of MAPKAP kinase-la is 
essential jbr peptide phosphorylation 
MAPKAP kinase- 1 possesses two protein kinase domains in 
the same polypeptide [31]. The N-terminal or C-terminal kinase 
domains of MAPKAP kinase-la (p90rsk-‘) were inactivated by 
mutating the Asp residue of the conserved DFG motif in sub- 
domain 7 to Ala. Wild-type and mutant MAPKAP kinase-1 
tagged at the N-terminus with a peptide from haemagglutinin 
were transiently transfected into COS-1 cells. The cells were 
either incubated for 90 min with PD 98059 (an inhibitor of the 
activation of MAP kinase kinase [32]) to suppress the basal 
level of MAPKAP kinase-1 activity, or stimulated with phorbol 
myristate acetate to activate MAPKAP kinase-1. The enzymes 
were then immunoprecipitated from the lysates with antibody 
12CA5 that recognises the peptide tag, and assayed. As shown 
in Fig. lA, the mutant in which the C-terminal kinase domain 
had been inactivated retained about 30% of the activity of the 
wild-type enzyme towards (G245/G246)S2’8-249 and about 40% of 
the activity towards KKKNRTLSVA and two peptide 
substrates with RRxS motifs, LRRASLG and RRLSSLRA 
(Fig. 1B). In contrast, the mutant in which the N-terminal 
domain of MAPKAP kinase-1 was inactivated failed to phos- 
phorylate any peptide tested (Fig. 1). 
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Wild Type D557A mutant D205A mutant 
PM4 + - - + - - + - - 
PD 98059 - - + - - + - - + 
Wild Type D557A mutant D205A mutant 
Fig. 1. Effect of inactivating the N-terminal or C-terminal kinase do- 
mains of MAPKAP kinase-la on its activity towards different peptide 
substrates. (A) COS-1 cells were grown on 10 cm plates, and transiently 
transfected with wild type (WT) MAPKAP kinase-la or the D205A or 
D557A mutants as in 1361. Cells were then grown in DMEM. 10% FCS 
for 48 h, serum starved ;n DMEM, O.S%-FCS for 3 h, the drug PD 
98059 being added after 1.5 h where indicated. Cells incubated in the 
absence of PD 98059, were stimulated for 15 min with 0.1 ,uM phorbol 
myristate acetate (PMA) and lysed in buffer [37] supplemented with 
2pM microcystin. After centrifugation for 5 min at 13,000 x g, aliquots 
of the supernatants were immunoprecipitated with antibody 12CA5 
prebound to Protein G-Sepharose beads.The immunoprecipitates were 
washed twice with lysis buffer containing 0.5 M NaCl, twice with 50 
mM MOPS, pH 7.0,O.l mM EGTA, 0.1% (by vol.) 2-mercaptoethanol, 
0.03% (by mass) Brij 35, 2pM microcystin, and assayed for_MAPKAP 
kinase-1 activity with the peptide (G245/G’46)S62’8 2“9. Control experi- 
ments were carried out in parallel in which the cells were transfected 
with expression vector alone. These values were typically 5% of the 
PMA-stimulated activity. Immunoblotting experiments showed that 
the levels of expression of MAPKAP kinase-I were similar in all trans- 
fections. (B) The experiment was carried out as in (A), and the figure 
shows the activity of immunoprecipitates from PD 98059-treated cells 
subtracted from the activity in immunoprecipitates from PMA stimu- 
lated cells towards the peptides KKKNRTLSVA (filled bars), 
LRRASLG (hatched bars) or RRLSSLRA (open bars). 
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4. Discussion 
The present results establish that the specificities of 
M APKAP kinase- 1 and ~70~~~ are far more similar than real- 
iszd previously. Both enzymes require Arg at position n - 3 and 
Arg (or Lys) at position n - 5, explaining why both enzymes 
p’rosphorylate the same serine residues in GSK3 and S6 (see 
section 1). However, the requirement for a basic residue at 
p ysition n - 5 can be overcome, at least partially, by the pres- 
ei ce of Arg or Lys at other positions N-terminal to the site of 
p rosphorylation. This presumably explains why MAPKAP ki- 
n tse-1 is able to phosphorylate serine residues in the GM-sub- 
u tit of PPl [ 131, tyrosine hydroxylase [lo] and peptides [22] that 
Ii.: in RRxS sequences, while p70ShK was reported to phospho- 
r late this motif in the transcription factor CREM [33]. 
The structure of MAPKAP kinase-1 is unusual in that two 
p .otein kinase domains are present in a single polypeptide [31]. 
T he N-terminal domain is most similar to ~70”~ kinase (nearly 
6’1% sequence identity) [34], and the present results suggest that 
t! is is the domain which phosphorylates both RxRxxS and 
RRxS motifs, since mutation of the Asp in the conserved N- 
tt rminal DFG motif in subdomain VII abolished activity to- 
v ards all peptides examined. In contrast, mutation of the corre- 
slonding Asp in the C-terminal DFG motif decreased activity 
b f 60-70%. As this paper was about to be submitted, Bjorbaek 
e al. [35] also reported that inactivation of the N-terminal 
d Imain of the isoform MAPKAP kinase-I y (p90”h-3) by muta- 
t on of Lys” abolished activity, and that inactivation of the 
< -terminal domain by mutation of Ly?“ reduced activity by 
a similar amount to that reported here. The partial loss of 
h IAPKAP kinase-1 activity towards peptide substrates result- 
i: lg from inactivation of the C-terminal domain may be ex- 
f lained if the C-terminal kinase domain is required to enhance 
t re activity of the N-terminal kinase domain by auto- 
f hosphorylating one or more residues. 
p70ShK cannot phosphorylate peptides which have less than 
f ve residues N-terminal to the phosphorylated serine, explain- 
i rg its failure to phosphorylate several substrates for MAPKAP 
k inase-1, such as LRRASLG ([20] and see Table 1). However, 
I 70 ShK is much more tolerant of Thr at the site of phosphoryl- 
a tion than MAPKAP kinase-1 and, in contrast to MAPKAP 
b inase-1, no residue is required at position n + 2 (Table 2). 
? hese differences have allowed us to develop the first peptide 
s rbstrate which shows a high degree of selectivity for ~70~~~ 
( ver MAPKAP kinase-I, and which should prove useful for 
f rture studies of this enzyme. 
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